HTLV-II Infections

Diseases caused by HUMAN T-LYMPHOTROPIC VIRUS 2.

Also Known As:

Human T-lymphotropic Virus 2 Infection; Human T-lymphotropic Virus 2 Infections; Infections, HTLV-II; HTLV-II Infection; Human T lymphotropic Virus 2 Infection; Human T lymphotropic Virus 2 Infections; Infection, HTLV-II; Infections, HTLV II

Networked: 51 relevant articles (4 outcomes, 4 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	HTLV-II Infections
2.	Infections
3.	Peripheral Nervous System Diseases (PNS Diseases)
4.	Non-Hodgkin Lymphoma (Lymphosarcoma)
5.	HTLV-I Infections (HTLV-I Infection)

Experts

1.	Murphy, Edward L: 2 articles (07/2010 - 04/2005)
2.	Hall, W W: 2 articles (10/2000 - 05/2000)
3.	Kaplan, M H: 2 articles (10/2000 - 05/2000)
4.	Lewis, M J: 2 articles (10/2000 - 05/2000)
5.	Biswas, Hope H: 1 article (07/2010)
6.	Fridey, Joy L: 1 article (07/2010)
7.	Garratty, George: 1 article (07/2010)
8.	Gibble, Joan W: 1 article (07/2010)
9.	HTLV Outcomes Study: 1 article (07/2010)
10.	Kaidarova, Zhanna: 1 article (07/2010)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to HTLV-II Infections:

1.	AntigensIBA 11/10/1990 - "Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection." 05/01/1991 - "To understand the pathogenic potential and the true extent of human T-cell leukemia virus type II (HTLV-II) infection, it is important to develop a specific HTLV-II antigen-based serological test. " 02/01/2003 - "The results indicate that chimeric peptide as coating antigen is very useful for the immunodiagnosis of HTLV-II infection." 05/15/1992 - "Recombinant antigens containing this epitope should be useful for type-specific serologic diagnosis of HTLV-II infection." 03/01/1998 - "Our data stress high prevalences of both HTLV-I and HTLV-II infections in HIV-1 coinfected i.v. drug users from São Paulo, and suggests that ELISA kits containing only K55 protein as the HTLV-II-specific antigen, may not have the appropriate sensitivity for the detection of HTLV-II infection in this geographic region, pointing out the need of improved screening tests to be used in Brazil."
2.	Proteins (Proteins, Gene)FDA Link 05/25/2000 - "Recently, studies on HTLV-II infections in Brazil have revealed isolates that are related phylogenetically to the HTLV-IIa subtype but have a HTLV-IIb phenotype with respect to the transactivating protein, tax. " 01/01/1991 - "In a series of 962 intravenous drug addicts (IVDAs) and 50 patients with haematological malignancies, 51 and 2 samples, respectively, were reactive against HTLV-I proteins; among these, HTLV-I infection was confirmed only in 1 patient with adult T-cell lymphoma, while HTLV-II infections were identified in 6 out of 14 PCR-tested IVDAs. " 10/01/1991 - "Synthetic peptide assays, employing peptides derived from the core and envelope proteins of HTLV-I and HTLV-II (SynthEIA and Select-HTLV tests), were evaluated for the ability to serologically discriminate HTLV-I and HTLV-II infections. " 03/01/1998 - "Our data stress high prevalences of both HTLV-I and HTLV-II infections in HIV-1 coinfected i.v. drug users from São Paulo, and suggests that ELISA kits containing only K55 protein as the HTLV-II-specific antigen, may not have the appropriate sensitivity for the detection of HTLV-II infection in this geographic region, pointing out the need of improved screening tests to be used in Brazil." 04/01/1994 - "To confirm and discriminate HTLV-I and HTLV-II infections, sera presenting any bands on WB were further analyzed by a WB containing recombinant HTLV-I and HTLV-II proteins (WB 2.3), and by enzyme immunoassays using synthetic peptides specific for envelope proteins (Synth-EIA). "
3.	Peptides (Polypeptides)IBA 01/01/1996 - "These results suggest that peptide vaccination with a synthetic peptide corresponding to the HTLV-II neutralization region is useful for preventing HTLV-II infection." 01/01/1996 - "Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region." 11/01/1993 - "HTLV-II infection was confirmed in 8 cases by HTLV-specific, synthetic peptide EIAs and PCR on uncultured cells; restriction analysis of the PCR-amplified env regions revealed the presence of HTLV-II/b strains in all 8 cases. " 01/01/1993 - "Detection of HTLV-I and HTLV-II infection in Africans using type-specific envelope peptides." 01/01/1991 - "To discriminate between HTLV-I and HTLV-II infections, we employed synthetic peptides specific for HTLV-I and HTLV-II env regions, and the polymerase chain reaction (PCR). "
4.	VaccinesIBA 12/01/1994 - "These new observations will be helpful in developing vaccines against HTLV-II infection." 01/01/1994 - "A vaccine is needed because in developing countries there are no other feasible preventive interventions against these diseases and in Western countries intravenous drug users at high risk for HTLV-I and HTLV-II infections and the health workers in contact with such populations must be protected. " 04/15/2005 - "To determine whether HTLV-II infection is associated with impaired humoral immune responses, we immunized a cohort of HTLV-II-infected subjects and matched uninfected control subjects with 23-valent pneumococcal polysaccharide and tetanus toxoid vaccines. "
5.	Immunoglobulin G (IgG)IBA 03/01/1994 - "These findings indicate that passive immunization with II-IgG is effective in preventing HTLV-II infection and that there is no cross-neutralization between HTLV-I and -II." 03/01/1994 - "Hyperimmune globulins, I-IgG and II-IgG, prepared from healthy persons seropositive for human T cell lymphotropic virus (HTLV) types I and II, respectively, were tested for their prophylactic effect against HTLV-II infection in rabbits. "
6.	DNA (Deoxyribonucleic Acid)IBA 08/01/2000 - "Thus, optimal detection of HTLV-II infection would seem to require both serologic and DNA PCR assays." 12/01/1991 - "To determine whether these individuals were infected with HTLV-I and/or HTLV-II, DNA samples were also amplified with HTLV-II specific primers and no evidence of HTLV-II infection was observed. " 06/15/1991 - "DNA amplification on 65 of the 207 HTLV-I/II seropositive donors revealed that 34 (52%) had HTLV-II infection and 28 (43% had HTLV-I; 3 samples were uninformative. " 04/01/1995 - "Because of the absence of its antibody, HTLV-II infection was not confirmed in these patients, but the presence of HTLV-II proviral DNA or its related DNA at high frequency suggests a relationship of HTLV-II with the development of autoimmune thyroid diseases." 02/01/1992 - "The results indicate the absence of HTLV-I and -II infection in individuals with indeterminate WB, the presence of HTLV-I DNA in individuals positive for WB in the French West Indies, and the absence of HTLV-II infection in the cohort."
7.	Glycoproteins (Glycoprotein)IBA 07/01/1995 - "In an attempt to suppress HTLV-II infection, we first generated HTLV-II env precursor glycoprotein (gp63) using baculovirus vector and the Sf-9 cell system. " 01/01/1992 - "These findings indicate that these antisera specifically recognized the envelope glycoprotein (gp46) of HTLV-II and suggest the specificity of this region in the immune response to HTLV-II. Such antisera are useful in distinguishing between HTLV-I and HTLV-II infection and in determining the presence of individual HTLV-II-infected cells both in vivo and in vitro, including non-lymphoid cells. " 01/01/1994 - "At the same dilution, antisera inhibited 70 to 80% of infection of BJAB-WH cells by cell-free HTLV-I or HTLV-II. Thus, these studies indicate a role for a 78- to 80-kDa glycoprotein in HTLV-I or HTLV-II infection and syncytium formation."
8.	Immune Sera (Antisera)IBA 01/01/1992 - "These findings indicate that these antisera specifically recognized the envelope glycoprotein (gp46) of HTLV-II and suggest the specificity of this region in the immune response to HTLV-II. Such antisera are useful in distinguishing between HTLV-I and HTLV-II infection and in determining the presence of individual HTLV-II-infected cells both in vivo and in vitro, including non-lymphoid cells. " 01/01/1994 - "At the same dilution, antisera inhibited 70 to 80% of infection of BJAB-WH cells by cell-free HTLV-I or HTLV-II. Thus, these studies indicate a role for a 78- to 80-kDa glycoprotein in HTLV-I or HTLV-II infection and syncytium formation."
9.	env Gene ProductsIBA 07/01/1995 - "In the studies to determine if vaccination could protect against HTLV-II infection, rabbits were first immunized with the env protein, then were challenged by inoculation with HTLV-II-Vines as described above. "
10.	EnzymesIBA 03/01/1998 - "Thirty-five sera were tested by an enzyme immune assay, and a Western blot that discriminates HTLV-I and HTLV-II infection. " 11/01/1992 - "Rapid discrimination between HTLV-I and HTLV-II infections was achieved by restriction enzyme analysis of unpurified second-round PCR products, even in those cases in which serological assays had failed to provide a definitive result. " 11/01/1992 - "Differential diagnosis of HTLV-I and HTLV-II infections by restriction enzyme analysis of 'nested' PCR products." 06/01/1993 - "We describe enzyme immunoassays that use synthetic oligopeptides to discriminate serologically between human T-cell lymphotropic virus type I and II (HTLV-I and HTLV-II) infections. " 05/01/1993 - "In order to assess the specificity and sensitivity of two peptide-based assays (Synth HTLV-I and HTLV-II enzyme-linked immunoassay [EIA] [UBI] and Select-HTLV EIA [IAF]) in discriminating between antibody to HTLV-I and HTLV-II infection, a panel of 186 well-characterised serum/plasma samples was tested by the two assays. "

Therapies and Procedures

1.	Blood Transfusion (Blood Transfusions) 07/01/1997 - "We confirmed the presence of HTLV-I and HTLV-II infections in blood donors (0.4% and 0.1%, respectively), in patients exposed to multiple blood transfusions (10.2% and 0.8%, respectively), and in 30 (27.5%) of 109 family members of HTLV-I- or HTLV-II-infected patients. " 04/01/1991 - "As a consequence of migrating populations, IV drug use and, to a lesser extent, blood transfusions, endemic HTLV-I and HTLV-II infections have spread to nonendemic geographic regions. "
2.	Donor Selection 10/01/1992 - "Before donor screening for HTLV-I, transfusion of 51,026 units resulted in two HTLV-I infections (0.0039%) and four HTLV-II infections (0.0078%). "
3.	Therapeutics 01/01/2006 - "Five coinfected subjects undergoing antiretroviral therapy showed a significant (P < 0.05) increase in HTLV-II proviral load concomitant to a decrease in HIV-1 viremia, suggesting that the treatment is ineffective against HTLV-II infection."
4.	Intravenous Injections 07/01/1995 - "HTLV-II infection in rabbits was produced by intravenous injection of HTLV-II-Vines into female rabbits (New Zealand White). "